In PTCs, BRAF (V600E) mutation was associated with the presence of minimal extrathyroidal extension (miETE; 59.1% of the BRAF mutated tumours have miETE vs. 26.1% of the BRAF wild type tumours; p = 0.004) and with the presence of lymphocytic infiltrate (66.7% of the BRAF mutated tumours have lymphocytic infiltration vs. 35.7% of the wild type tumours ̧ p = 0.012). The gene discussed is BRAF; the disease is neoplasm.